



NAPLEX Blueprint Crosswalk

December 2024

No part of this publication may be reproduced in any manner without the written permission of the executive director/secretary of the National Association of Boards of Pharmacy.

©2024 by the National Association of Boards of Pharmacy. All rights reserved.

Introduction

Following the completion of the North American Pharmacist Licensure Examination[®] (NAPLEX[®]) Practice Analysis, initiated in Spring 2024, the National Association of Boards of Pharmacy (NABP) undertook a comprehensive crosswalk activity to align the current (2021) NAPLEX competency statements with the updated (2025) content outline. This process involved leveraging the expertise of subject-matter experts from the pharmacy field to systematically compare and map each competency area in the existing framework to one or more subdomains in the new content outline. By doing so, NABP's competency assessment team ensured a clear correlation between the established 2021 competency statements and the updated 2025 content outline.

The crosswalk serves as a tool to illustrate how the current NAPLEX competency framework aligns with and supports the forthcoming updates to the exam. Apart from the 5 new subdomains in the 2025 content outline, every competency statement from 2021 is associated with one or more subdomains in the upcoming 2025 content outline. The practice analysis demonstrated a need to further integrate foundational pharmacy practice and medication use process knowledge into a holistic patient centered approach to ensure entry-level pharmacists can develop and manage treatment plans for specific patient cases.

The updated NAPLEX content outline breaks down the overarching competency statements into specific content areas (domains, subdomains, and sub-subdomains). These subdomains ensure candidates' competency is assessed comprehensively by targeting knowledge, skills, and abilities. Domains, on the other hand, organize the competency areas into specific content categories, grouping related tasks and responsibilities to structure the exam framework systematically.

The following crosswalk table compares the current (2021) competency statements to the updated (2025) content outlines.

Example:

1. Foundational Knowledge for Pharmacy Practice (DOMAIN)

A. Pharmaceutical science principles and concepts (Subdomain)

1. Pharmacology (Sub-subdomain)

Crosswalk Table

2021 Competency Statement	2025 Content Domains
1.1	1A2
<p>Area 1 – Obtain, Interpret, or Assess Data, Medical, or Patient Information</p> <p>1.1 – From instruments, screening tools, laboratory, genomic or genetic information, or diagnostic findings</p>	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1A. Pharmaceutical science principles and concepts</p> <p>1A2. Pharmacokinetics, pharmacodynamics, or pharmacogenomics</p>
1.2	2C2 3A 3B 3C1 3C7
<p>Area 1 – Obtain, Interpret, or Assess Data, Medical, or Patient Information</p> <p>1.2 – From patients: treatment adherence, or medication-taking behavior; chief complaint, medication history, medical history, family history, social history, lifestyle habits, socioeconomic background</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2C. Immunization services and documentation</p> <p>2C2. Contraindications and precautions</p> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3A. Medication history, allergy history, and reconciliation</p> <p>3B. Health histories, screenings, and assessments</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C1. Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology</p> <p>3C7. Adherence</p>
1.3	3A 3C7
<p>Area 1 – Obtain, Interpret, or Assess Data, Medical, or Patient Information</p> <p>1.3 – From practitioners: treatment adherence, or medication-taking behavior; chief complaint, medication history, medical history, family history, social history, lifestyle habits, socioeconomic background</p>	<p>3. Person-Centered Assessment and Treatment Planning</p> <p>3A. Medication history, allergy history, and reconciliation</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C7. Adherence</p>

1.4	3A 3C1 3C7
<p>Area 1 – Obtain, Interpret, or Assess Data, Medical, or Patient Information</p> <p>1.4 – From medical records: treatment adherence, or medication-taking behavior; chief complaint, medication history, medical history, family history, social history, lifestyle habits, socioeconomic background</p>	<p>3. Person-Centered Assessment and Treatment Planning</p> <p>3A. Medication history and reconciliation</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C1. Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology</p> <p>3C7. Adherence</p>
1.5	3B 3C1 3C2 3C5 3E3
<p>Area 1 – Obtain, Interpret, or Assess Data, Medical, or Patient Information</p> <p>1.5 – Signs or symptoms of medical conditions, healthy physiology, etiology of diseases, or pathophysiology</p>	<p>3. Person-Centered Assessment and Treatment Planning</p> <p>3B. Health histories, screenings, and assessments</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C1. Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology</p> <p>3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)</p> <p>3C5. Adverse drug reactions</p> <p>3E. Patient education</p> <p>3E3. Disease state management</p>
1.6	3B 3C1 3E1
<p>Area 1 – Obtain, Interpret, or Assess Data, Medical, or Patient Information</p> <p>1.6 – Risk factors or maintenance of health and wellness</p>	<p>3. Person-Centered Assessment and Treatment Planning</p> <p>3B. Health histories, screenings, and assessments</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C1. Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology</p> <p>3E. Patient education</p> <p>3E1. Lifestyle modifications and health maintenance</p>

1.7	1F
<p>Area 1 – Obtain, Interpret, or Assess Data, Medical, or Patient Information</p> <p>1.7 – Evidence-based literature or studies using primary, secondary, and tertiary references</p>	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1F. Retrieval, assessment, and interpretation of primary, secondary, and tertiary resources</p>
2.1	1A1 1A2 2A1 2A2 2A5 3C2 3C3 3C5 3C6 3D3
<p>Area 2 – Identify Drug Characteristics</p> <p>2.1 – Pharmacology, mechanism of action, or therapeutic class</p>	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1A. Pharmaceutical science principles and concepts</p> <p>1A1. Pharmacology</p> <p>1A2. Pharmacokinetics, pharmacodynamics, or pharmacogenomics</p> <hr/> <p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A1. Drug names and therapeutic classes</p> <p>2A2. Indications, usage, and dosing regimens</p> <p>2A5. Safety and effectiveness (eg, laboratory parameters, vital signs)</p> <hr/> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)</p> <p>3C3. Interactions (eg, drug-drug, drug-condition, drug-food, drug-allergy, drug-laboratory)</p> <p>3C5. Adverse drug reactions</p> <p>3C6. Toxicologic exposures and overdoses</p> <p>3D. Therapeutic monitoring, plan development, evaluation, and modifications</p> <p>3D3. Effectiveness</p>

2.2	2A1 2A2 2A3 2B
<p>Area 2 – Identify Drug Characteristics</p> <p>2.2 – Commercial availability; prescription or non-prescription status; brand, generic, or biosimilar names; physical descriptions; or how supplied</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A1. Drug names and therapeutic classes</p> <p>2A2. Indications, usage, and dosing regimens</p> <p>2A3. Available dosage forms</p> <p>2B. Therapeutic substitutions (eg, formulary restrictions, therapeutic alternatives, shortages, biosimilars)</p>
2.3	2A4
<p>Area 2 – Identify Drug Characteristics</p> <p>2.3 – Boxed warnings or REMS</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A4. Prescription regulations (eg, boxed warnings, risk evaluation and mitigation strategies)</p>
2.4	2C1 2C2 3C2 3D2
<p>Area 2 – Identify Drug Characteristics</p> <p>2.4 – Pregnancy or lactation</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2C. Immunization services and documentation</p> <p>2C1. Indications and scheduling</p> <p>2C2. Contraindications and precautions</p> <hr/> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)</p> <p>3D. Therapeutic monitoring, plan development, evaluation, and modifications</p> <p>3D2. Safety</p>

3.1	3F
<p>Area 3 – Develop or Manage Treatment Plans 3.1 – Triage or medical referral</p>	<p>3. Person-Centered Assessment and Treatment Planning 3F. Over-the-counter medications and dietary supplements</p>
3.2	3D1 3D2 3D3 3E3
<p>Area 3 – Develop or Manage Treatment Plans 3.2 – Therapeutic goals or outcomes and clinical endpoints</p>	<p>3. Person-Centered Assessment and Treatment Planning 3D. Therapeutic monitoring, plan development, evaluation, and modifications 3D1. Therapeutic goals, clinical endpoints, and follow-up 3D2. Safety 3D3. Effectiveness 3E. Patient education 3E3. Disease state management</p>
3.3	2A2 3C2 3C4 3D1 3D3
<p>Area 3 – Develop or Manage Treatment Plans 3.3 – Medication reconciliation; indication or therapeutic uses; lack of indication; inappropriate indication; duplication of therapy; omissions</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) 2A. Prescriptions and medication order interpretation 2A2. Indications, usage, and dosing regimens</p>
	<p>3. Person-Centered Assessment and Treatment Planning 3C. Patient health conditions including special populations and medication-related factors 3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making) 3C4. Errors and omissions (eg, dosing, duplication, additional therapy needed, unnecessary therapy) 3D. Therapeutic monitoring, plan development, evaluation, and modifications 3D1. Therapeutic goals, clinical endpoints, and follow-up 3D3. Effectiveness</p>

3.4	2A2 3C2 3D1 3D3
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.4 – Drug dosing or dosing adjustments; duration of therapy</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A2. Indications, usage, and dosing regimens</p> <hr/> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)</p> <p>3D. Therapeutic monitoring, plan development, evaluation, and modifications</p> <p>3D1. Therapeutic goals, clinical endpoints, and follow-up</p> <p>3D3. Effectiveness</p>
3.5	2A2 2A3 3C2
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.5 – Drug route of administration, dosage forms, or delivery systems</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A2. Indications, usage, and dosing regimens</p> <p>2A3. Available dosage forms</p> <hr/> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)</p>

3.6	2A4 2A5 2C2 3C2 3C3 3D2
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.6 – Drug contraindications, allergies, or precautions</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A4. Prescription regulations (eg, boxed warnings, risk evaluation and mitigation strategies)</p> <p>2A5. Safety and effectiveness (eg, laboratory parameters, vital signs)</p> <p>2C. Immunization services and documentation</p> <p>2C2. Contraindications and precautions</p> <hr/> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)</p> <p>3C3. Interactions (eg, drug-drug, drug-condition, drug-food, drug-allergy, drug-laboratory)</p> <p>3D. Therapeutic monitoring, plan development, evaluation, and modifications</p> <p>3D2. Safety</p>
3.7	2A5 2C5 3C2 3C3 3C5 3C6 3D2 3D3 3E2
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.7 – Adverse drug effects, toxicology, or overdose</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A5. Safety and effectiveness (eg, laboratory parameters, vital signs)</p> <p>2C. Immunization services and documentation</p> <p>2C5. Adverse reactions</p>

<p><i>(3.7 continued)</i></p> <p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.7 – Adverse drug effects, toxicology, or overdose</p>	<p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)</p> <p>3C3. Interactions (eg, drug-drug, drug-condition, drug-food, drug-allergy, drug-laboratory)</p> <p>3C5. Adverse drug reactions</p> <p>3C6. Toxicologic exposures and overdoses</p> <p>3D. Therapeutic monitoring, plan development, evaluation, and modifications</p> <p>3D2. Safety</p> <p>3D3. Effectiveness</p> <p>3E. Patient education</p> <p>3E2. Medication use, storage, and disposal</p>
3.8	1A2 3C3 3D2 3D3 3E3
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.8 – Drug interactions</p>	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1A. Pharmaceutical science principles and concepts</p> <p>1A2. Pharmacokinetics, pharmacodynamics, or pharmacogenomics</p> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C3. Interactions (eg, drug-drug, drug-condition, drug-food, drug-allergy, drug-laboratory)</p> <p>3D. Therapeutic monitoring, plan development, evaluation, and modifications</p> <p>3D2. Safety</p> <p>3D3. Effectiveness</p> <p>3E. Patient education</p> <p>3E3. Disease state management</p>

3.9	2A5 3D1 3D2 3D3 3E3
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.9 – Therapeutic monitoring parameters, monitoring techniques, monitoring tools, or monitoring frequency</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A5. Safety and effectiveness (eg, laboratory parameters, vital signs)</p> <hr/> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3D. Therapeutic monitoring, plan development, evaluation, and modifications</p> <p>3D1. Therapeutic goals, clinical endpoints, and follow-up</p> <p>3D2. Safety</p> <p>3D3. Effectiveness</p> <p>3E. Patient education</p> <p>3E3. Disease state management</p>
3.10	1A2
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.10 – Drug pharmacokinetics or pharmacodynamics</p>	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1A. Pharmaceutical science principles and concepts</p> <p>1A2. Pharmacokinetics, pharmacodynamics, or pharmacogenomics</p>
3.11	3C2 3D3 3F
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.11 – Evidence-based practice</p>	<p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors</p> <p>3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)</p> <p>3D. Therapeutic monitoring, plan development, evaluation, and modifications</p> <p>3D3. Effectiveness</p> <p>3F. Over-the-counter medications and dietary supplements</p>

3.12	2A2 3C2 3E1 3E3 3F 3G
<p>Area 3 – Develop or Manage Treatment Plans</p> <p>3.12 – Non-drug therapy: lifestyle, self-care, first-aid, complementary and alternative medicine, or medical equipment</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation 2A2. Indications, usage, and dosing regimens</p> <hr/> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3C. Patient health conditions including special populations and medication-related factors 3C2. Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making) 3E. Patient education 3E1. Lifestyle modifications and health maintenance 3E3. Disease state management 3F. Over-the-counter medications and dietary supplements 3G. Devices to administer medications and self-monitoring tests</p>
4.1	1C1
<p>Area 4 – Perform Calculations</p> <p>4.1 – Patient parameters or laboratory measures</p>	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1C. Pharmaceutical calculations 1C1. Patient parameters or laboratory measures</p>
4.2	1C2
<p>Area 4 – Perform Calculations</p> <p>4.2 – Quantities of drugs to be dispensed or administered</p>	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1C. Pharmaceutical calculations 1C2. Quantities of drugs to be dispensed or administered</p>
4.3	1C3
<p>Area 4 – Perform Calculations</p> <p>4.3 – Rates of administration</p>	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1C. Pharmaceutical calculations 1C3. Rates of administration</p>

4.4	1C4
Area 4 – Perform Calculations 4.4 – Dose conversions	1. Foundational Knowledge for Pharmacy Practice 1C. Pharmaceutical calculations 1C4. Dose conversions
4.5	1C5
Area 4 – Perform Calculations 4.5 – Drug concentrations, ratio strengths, osmolarity, osmolality, or extent of ionization	1. Foundational Knowledge for Pharmacy Practice 1C. Pharmaceutical calculations 1C5. Drug concentrations, ratio strengths, osmolarity, or osmolality
4.6	1C6
Area 4 – Perform Calculations 4.6 – Quantities of drugs or ingredients to be compounded	1. Foundational Knowledge for Pharmacy Practice 1C. Pharmaceutical calculations 1C6. Quantities of drugs or ingredients to be compounded
4.7	1C7
Area 4 – Perform Calculations 4.7 – Nutritional needs and the content of nutrient sources	1. Foundational Knowledge for Pharmacy Practice 1C. Pharmaceutical calculations 1C7. Nutritional needs and the content of nutrient sources
4.8	1C8
Area 4 – Perform Calculations 4.8 – Biostatistics, epidemiological, or pharmaco-economic measures	1. Foundational Knowledge for Pharmacy Practice 1C. Pharmaceutical calculations 1C8. Biostatistics, epidemiological, or pharmaco-economic measures
4.9	1C9
Area 4 – Perform Calculations 4.9 – Pharmacokinetic parameters	1. Foundational Knowledge for Pharmacy Practice 1C. Pharmaceutical calculations 1C9. Pharmacokinetic parameters

5.1	1A2 1A3 1B1 1B2 2D
<p>Area 5 – Compound, Dispense, or Administer Drugs, or Manage Delivery Systems</p> <p>5.1 – Physicochemical properties of drug products affecting compatibility, stability, delivery, absorption, onset, duration, distribution, metabolism, or elimination</p>	<p>1. Foundational Knowledge for Pharmacy Practice 1A. Pharmaceutical science principles and concepts 1A2. Pharmacokinetics, pharmacodynamics, or pharmacogenomics 1A3. Pharmaceuticals 1B. Pharmaceutical compounding 1B1. Nonsterile preparations 1B2. Sterile preparations</p> <p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) 2D. Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control)</p>
5.2	1B2
<p>Area 5 – Compound, Dispense, or Administer Drugs, or Manage Delivery Systems</p> <p>5.2 – Techniques, procedures, or equipment for hazardous or non-hazardous sterile products</p>	<p>1. Foundational Knowledge for Pharmacy Practice 1B. Pharmaceutical compounding 1B2. Sterile preparations</p>
5.3	1B1
<p>Area 5 – Compound, Dispense, or Administer Drugs, or Manage Delivery Systems</p> <p>5.3 – Techniques, procedures, or equipment for hazardous or non-hazardous non-sterile products</p>	<p>1. Foundational Knowledge for Pharmacy Practice 1B. Pharmaceutical compounding 1B1. Nonsterile preparations</p>

5.4	2C 2D 3E2 3G
<p>Area 5 – Compound, Dispense, or Administer Drugs, or Manage Delivery Systems</p> <p>5.4 – Equipment or delivery systems</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2C. Immunization services and documentation</p> <p>2D. Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control)</p> <hr/> <p>3. Person-Centered Assessment and Treatment Planning</p> <p>3E. Patient education</p> <p>3E2. Medication use, storage, and disposal</p> <p>3G. Devices to administer medications and self-monitoring tests</p>
5.5	2A2 2C4 3E2 3E3
<p>Area 5 – Compound, Dispense, or Administer Drugs, or Manage Delivery Systems</p> <p>5.5 – Instructions or techniques for drug administration</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2A. Prescriptions and medication order interpretation</p> <p>2A2. Indications, usage, and dosing regimens</p> <p>2C. Immunization services and documentation</p> <p>2C4. Administration (eg, techniques, preparation, routes)</p> <hr/> <p>2. Person-Centered Assessment and Treatment Planning</p> <p>3E. Patient education</p> <p>3E2. Medication use, storage, and disposal</p> <p>3E3. Disease state management</p>
5.6	2C3 2D 3E2
<p>Area 5 – Compound, Dispense, or Administer Drugs, or Manage Delivery Systems</p> <p>5.6 – Packaging, storage, handling, or disposal</p>	<p>2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring)</p> <p>2C. Immunization services and documentation</p> <p>2C3. Storage and handling</p> <p>2D. Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control)</p>

(5.6 continued)	3. Person-Centered Assessment and Treatment Planning 3E. Patient education 3E2. Medication use, storage, and disposal
6.1	5A
Area 6 – Develop or Manage Practice or Medication-Use Systems to Ensure Safety and Quality 6.1 – Interdisciplinary practice, collaborative practice, or expanded practice responsibilities	5. Pharmacy Management and Leadership 5A. Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety)
6.2	5A
Area 6 – Develop or Manage Practice or Medication-Use Systems to Ensure Safety and Quality 6.2 – Continuity of care or transitions of care	5. Pharmacy Management and Leadership 5A. Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety)
6.3	4A 4B
Area 6 – Develop or Manage Practice or Medication-Use Systems to Ensure Safety and Quality 6.3 – Disease prevention or screening programs; or stewardship	4. Professional Practice 4A. Adverse drug event reporting and medication error reporting (eg, MedWatch, VAERS) 4B. Public health initiatives and risk prevention programs (eg, tobacco and nicotine cessation, antimicrobial stewardship, health screenings, opioid stewardship)
6.4	4C 5A 5C
Area 6 – Develop or Manage Practice or Medication-Use Systems to Ensure Safety and Quality 6.4 – Vulnerable populations, special populations, or risk prevention programs	4. Professional Practice 4C. Social determinants and drivers of health 5. Pharmacy Management and Leadership 5A. Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety) 5C. Quality improvement activities (eg, medication use evaluation, root cause analysis, continuous quality improvement)

6.5	5A
<p>Area 6 – Develop or Manage Practice or Medication-Use Systems to Ensure Safety and Quality</p> <p>6.5 – Pharmacy informatics</p>	<p>5. Pharmacy Management and Leadership</p> <p>5A. Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety)</p>

NEW Domain	1D 1 E
	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1D. Drug development processes (eg, clinical trial phases, emergency use authorizations)</p>
	<p>1. Foundational Knowledge for Pharmacy Practice</p> <p>1E. Research design principles and biostatistics (eg, blinding, randomization, biases, statistical tests and outcomes, ethics)</p>
NEW Domain	4D
	<p>4. Professional Practice</p> <p>4D. Ethical considerations (eg, informed consent, ethical principles, professional conduct and responsibility, patient confidentiality)</p>
NEW Domain	5B 5D
	<p>5. Pharmacy Management and Leadership</p> <p>5B. Inventory and supply management (eg, drug recalls, drug shortages)</p>
	<p>5. Pharmacy Management and Leadership</p> <p>5D. Mentorship and preceptorship (eg, providing and receiving feedback, delegation of work activities, preceptor roles)</p>